Financial
Latest full-year results from official filings.
FY2026 revenue $401.9m (-12.3%); operating margin -6.6%; net loss $49.2m.
Cash $41.2m; debt $147.9m.
- Official results release · Accuray · 30 Jun 2026
Accuray: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Dec 2025: Accuray announced it would cut about 15% of its global workforce in a reorganisation. Feb 2026: it disclosed errors in revenue-obligation disclosures in prior reports, filed late for its quarterly report and said amended filings would follow.
- Madison-based medical equipment maker Accuray to lay off 15% of global workforce · BizTimes · 16 Dec 2025
- Accuray Form 12b-25 Notification of Late Filing · Accuray (SEC filing) · 9 Feb 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Accuray found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Jun 2026: Accuray began a Class 2 FDA recall of CyberKnife systems with the Xchange collimator changer, as a collimator that fails to dock may fall from its housing if motion is started from the in-room pendant.
- Class 2 Device Recall Accuray CyberKnife (Z-2644-2026) · US FDA · 1 Jul 2026
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable NHS contracts, troubled implementations, disputes or terminations involving Accuray found in HSH's search of the last 24 months.